Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly EBITDA Margin of 22.48% for Q1 2026, up 113203.0% year-over-year from N/an in Q1 2025, and up 75.64% quarter-over-quarter from 92.28% in Q4 2025.
Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's EBITDA Margin history runs 17 years deep, the most recent figure standing at 22.48% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 113203.0% year-over-year to 22.48%; the TTM figure through Mar 2026 stood at 83.29% (up 45616.0% YoY), while the FY2025 annual figure was 346.15%, down 3818.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 22.48%, up from 92.28% in the prior quarter.
- The five-year high for EBITDA Margin was 22.48% in Q1 2026, with the low at 1154.51% in Q1 2025.
- The 5-year median for EBITDA Margin is 191.64% (2022), against an average of 258.4%.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 94487 bps in 2025, then surged 113203 bps in 2026.
- Pacific Biosciences Of California's EBITDA Margin stood at 318.37% in 2022, then jumped by 53 bps to 150.02% in 2023, then plunged by 160 bps to 390.14% in 2024, then surged by 76 bps to 92.28% in 2025, then soared by 76 bps to 22.48% in 2026.
- Business Quant data shows PACB's EBITDA Margin at 22.48% in Q1 2026, 92.28% in Q4 2025, and 101.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.12 Bn | 193.52 Bn | 7.27 Bn | 13.44% |
| 2 | Stryker | 128.79 Bn | 125.32 Bn | 4.50 Bn | 25.18% |
| 3 | Medtronic | 119.30 Bn | 110.08 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 73.50 Bn | 72.96 Bn | 3.85 Bn | 21.65% |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.86 Bn | 1.35 Bn | 29.48% |
| 6 | Dexcom | 34.62 Bn | 32.67 Bn | 830.00 Mn | 24.33% |
| 7 | GE HealthCare Technologies | 34.05 Bn | 31.94 Bn | 2.18 Bn | 13.96% |
| 8 | Koninklijke Philips | 26.42 Bn | 23.10 Bn | 4.55 Bn | 10.30% |
| 9 | Steris | 23.15 Bn | 22.67 Bn | 684.20 Mn | 19.15% |
| 10 | Pacific Biosciences Of California | 397.95 Mn | 161.08 Mn | 12.64 Mn | -108.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -114.36% |
| Mar 31, 2026 | -22.48% |
| Dec 31, 2025 | -92.28% |
| Sep 30, 2025 | -101.13% |
| Jun 30, 2025 | -112.79% |
| Mar 31, 2025 | -1,154.51% |
| Dec 31, 2024 | -390.14% |
| Sep 30, 2024 | -160.32% |
| Jun 30, 2024 | -488.28% |
| Mar 31, 2024 | -209.64% |
| Dec 31, 2023 | -150.02% |
| Sep 30, 2023 | -148.12% |
| Jun 30, 2023 | -153.82% |
| Mar 31, 2023 | -234.58% |
| Dec 31, 2022 | -318.37% |
| Sep 30, 2022 | -230.94% |
| Jun 30, 2022 | -191.64% |
| Mar 31, 2022 | -233.69% |
| Dec 31, 2021 | -179.56% |
| Jun 30, 2021 | -122.75% |